Submitted by Anonymous (not verified) on 24 November 2023 - 13:20
Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Dermatitis, Atopic, Date of authorisation: 16/11/2023, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Dermatitis, Atopic, Date of authorisation: 16/11/2023, Status: Authorised